FDA Approves Merck’s RSV Prevention Treatment for Infants
The FDA has approved Merck's ENFLONSIA, a monoclonal antibody for preventing RSV lower respiratory tract disease in infants during their first RSV season, offering a single, weight-independent dose providing protection for about 5 months based on clinical trial success.